Cardiology

Evacetrapib fails to reduce major adverse cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol ...

Cardiology

Lixisenatide doesn't affect cardiovascular risk in T2DM

(HealthDay)—The addition of lixisenatide to usual care does not impact the rate of major cardiovascular events or other serious adverse events among patients with type 2 diabetes and a recent acute coronary syndrome, according ...

Diseases, Conditions, Syndromes

Discovery could speed up heart failure and pneumonia diagnosis

(Medical Xpress)—University of Otago researchers have discovered a potential new tool to help doctors in emergency departments quickly and accurately diagnose patients with heart failure and pneumonia.

page 3 from 5